Frontlight ResearchEarly access
Not yet taking people in PolandPhase 3
Testing CT-P13 injections for moderately to severely active rheumatoid arthritis
Tests CT-P13 injected under the skin in adults with active rheumatoid arthritis.
Key facts
- Who runs it
- Celltrion Inc.
- Where
- Bydgoszcz, Nadarzyn, Olsztyn, Plonsk, Tomaszów Lubelski, Warsaw, and Wroclaw, PolandSee the 10 sites
- Trial code
- Registry title
- A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 266 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 May 2028
- Type of study
- Interventional
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with moderately to severely active rheumatoid arthritis who already take methotrexate.
- Age
- 18 to 75 years old (both inclusive)
- Sex
- Men and women can join
- Disease stage
- Rheumatoid arthritis diagnosed at least 24 weeks before the first dose, with active disease: 6 or more swollen joints and 6 or more tender joints, plus raised CRP or ESR.
- Earlier treatment
- Must have taken methotrexate for at least 24 weeks, on a stable dose of 10 to 25 mg/week for at least 8 weeks. Must not have taken infliximab or targeted synthetic DMARDs such as tofacitinib or baricitinib.
- Biomarker or test result
- At least one of: positive anti-CCP, positive rheumatoid factor (RF), or, if both are negative, at least 1 bone erosion on X-ray.
Main reasons for not taking part
- Has taken infliximab before
- Has taken more than 2 biologic DMARDs for rheumatoid arthritis
- Did not respond well to a TNF alpha inhibitor
- Has taken a B-cell depleting drug such as rituximab
- Allergy to infliximab ingredients, murine or human proteins, or immunoglobulin products
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patient who is male or female aged 18 to 75 years old (both inclusive)
- Patient who has a diagnosis of RA at least 24 weeks prior to the first administration of the study drug (Day 1) and fulfill the 2010 ACR/EULAR classification criteria for RA
- Patient who has active disease as defined by the presence of 6 or more swollen joints (of 66 assessed), 6 or more tender joints (of 68 assessed) at Screening and baseline, and either a C-reactive protein (CRP) ≥1.0 mg/dL (≥10 mg/L) (at Screening) or an erythrocyte sedimentation rate (ESR) ≥28 mm/hour (at Screening and baseline)
- Patient who has at least one of the following at Screening: a) Positive for anti-cyclic citrullinated peptide (anti-CCP); or b) Positive for rheumatoid factor (RF); or c) If both RF and anti-CCP are negative, ≥1 bone erosions of the joints on X-ray on locally read screening X-ray
- Patient who has been receiving the treatment of oral or parenteral dosing with MTX for at least 24 weeks and has been on stable dosing with MTX between 10 to 25 mg/week for at least 8 weeks prior to the first administration of the study drug (Day 1)
Who cannot take part
- Patients who have previously received infliximab, for any purpose, cannot be enrolled
- Patient who has previously received investigational or licensed biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of RA, who meets any of following conditions a) Patient who has previously received more than 2 investigational or licensed bDMARDs for the treatment of RA, b) Patients with history of inadequate response to tumor necrosis factor (TNF) α inhibitor (the reason for discontinuation due to lack of efficacy), c) Patients who have received a B-cell depleting agent (e.g., rituximab) for the treatment of RA, d) Patients who have not met the required washout period prior to the first administration of study drug for the bDMARD specified below, or at least five times the mean terminal elimination half-life of the drug if not specified: • ≥ 4 weeks for etanercept; • ≥ 8 weeks for adalimumab, certolizumab, golimumab, abatacept, sarilumab and tocilizumab
- Patient who has previously received any investigational or licensed targeted synthetic DMARDs (e.g., tofacitinib, baricitinib) for the treatment of RA
- Patient who has allergies to any of the excipients of infliximab or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product
Where in Poland
- ZDROWIE OSTEO-MEDIC S.C. L. i A. Racewicz, A. i J. SupronikPolandNot yet recruiting
- Szpital Uniwersytecki nr 2 im dr Jana Biziela w BydgoszczyBydgoszcz, PolandNot yet recruiting
- NZOZ Lecznica MAK MED S CNadarzyn, PolandNot yet recruiting
- Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.Olsztyn, PolandNot yet recruiting
- Innova Clinic Sp. z o.o.Plonsk, PolandNot yet recruiting
- Samodzielny Publiczny Zespol Opieki Zdrowotnej W Tomaszowie LubelskimTomaszów Lubelski, PolandNot yet recruiting
- Klinika Reuma Park Sp. z o.o. S.K.Warsaw, PolandNot yet recruiting
- Medicover Integrated Clinical Services Sp. z o.o.Warsaw, PolandNot yet recruiting
- Rheuma Medicus Sp z o oWarsaw, PolandNot yet recruiting
- Niepubliczny Zaklad Opieki Zdrowotnej Biogenes Sp. z o.oWroclaw, PolandNot yet recruiting
About the trial
What the trial wants to find out
To demonstrate superiority of CT-P13 SC over Placebo in terms of efficacy as determined by clinical response according to the American College of Rheumatology (ACR) definition of a 50% improvement (ACR50) at Week 12.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
- Plain-language title
- Testing CT-P13 injections for moderately to severely active rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 October 2026